Study on Encorafenib, Binimetinib, Cemiplimab, and Fianlimab for Patients with BRAF-Mutated Melanoma and Brain Metastases

2 1 1 1

What is this study about?

This clinical trial is focused on studying a type of skin cancer called melanoma, specifically in patients who have a mutation known as BRAF and have cancer that has spread to the brain, causing symptoms. The study will use a combination of medications to see how effective they are in treating this condition. The medications involved are Encorafenib and Binimetinib, which are taken orally, followed by Cemiplimab and Fianlimab, which are given through an injection into a vein.

The purpose of the study is to evaluate how well these medications work together in preventing the cancer from getting worse in the brain over a period of six months. Participants will first receive Encorafenib and Binimetinib for a set period, and then switch to receiving Cemiplimab and Fianlimab. The study will monitor the participants’ health and the progression of their cancer during this time.

Throughout the study, participants will have regular check-ups and tests to track their response to the treatment. The study aims to provide valuable information on the effectiveness of this treatment combination for patients with BRAF-mutated melanoma and brain metastases, which are cancer cells that have spread to the brain. The results could help improve future treatment options for this condition.

1 beginning of treatment

Upon joining the clinical trial, the patient will begin treatment with two medications: encorafenib and binimetinib. These medications are taken orally. Encorafenib is available in two forms: 75 mg and 50 mg hard capsules. Binimetinib is provided as 15 mg film-coated tablets.

The patient will take these medications daily. The specific dosage and frequency will be determined by the healthcare provider based on individual needs and conditions.

2 transition to new treatment

After the initial phase with encorafenib and binimetinib, the patient will transition to a new treatment phase involving cemiplimab and fianlimab.

Cemiplimab is administered as a 350 mg concentrate for solution, given through an intravenous infusion. Fianlimab is also administered intravenously as a solution for injection.

The frequency and duration of these treatments will be specified by the healthcare provider, ensuring they align with the trial’s protocol.

3 monitoring and assessments

Throughout the trial, the patient will undergo regular monitoring and assessments to evaluate the effectiveness of the treatment and to check for any side effects.

These assessments may include physical examinations, laboratory tests, and imaging studies such as MRI to monitor brain metastases.

The healthcare team will assess the patient’s health status and adjust the treatment plan as necessary.

4 end of trial participation

At the end of the trial, the patient’s participation will conclude. The healthcare team will conduct a final assessment to evaluate the overall outcomes of the treatment.

The patient will receive guidance on any further steps or follow-up care needed after the trial.

Who Can Join the Study?

Provide written informed consent, which means you agree to participate after understanding the study details.
Have adequate liver function, which means your liver is working well enough based on specific blood tests.
Have a serum creatinine level that is not too high, indicating your kidneys are functioning properly.
Previous immunotherapy is allowed if any severe side effects have resolved.
Use of steroids or anticonvulsants is allowed if needed, as long as the dose hasn’t increased in the last 5 days before starting the study treatment.
If you are a woman who can have children, you must have a negative pregnancy test and agree to use effective birth control during the study and for 6 months after.
If you are a man with a partner who can have children, you must use condoms during the study and for 6 months after, unless you have had a vasectomy or practice abstinence.
Women must agree not to donate eggs, and men must agree not to donate sperm during the study and for 6 months after.
Be willing and able to attend scheduled visits and follow the study procedures.
Have a confirmed diagnosis of unresectable metastatic BRAF-mutated melanoma with brain metastases, which means the cancer has spread to the brain and cannot be removed by surgery.
Have brain metastases that cause symptoms, such as headaches or seizures, even if controlled with medication.
Have a documented BRAFV600 mutation in the tumor tissue, which is a specific change in the cancer cells.
Have a Modified Barthel Index score of more than 10, which measures your ability to perform daily activities.
Be at least 18 years old.
Have a performance status of ECOG PS 0-2, which means you are fully active or have some limitations but can still care for yourself.
Be able to swallow.
Have adequate blood cell counts, which means your blood tests show enough red blood cells, white blood cells, and platelets.

Who Cannot Join the Study?

Patients who do not have a specific type of skin cancer called BRAF-mutated melanoma cannot participate.
Patients who do not have symptomatic brain metastases (cancer that has spread to the brain and is causing symptoms) are not eligible.
Patients who are not within the specified age range for the study cannot join. The study is open to certain age groups only.
Both male and female patients are eligible, but those who do not meet other criteria will be excluded.
Patients who are considered part of a vulnerable population may not be eligible. This includes groups who may need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Hospital Clinico San Carlos	Madrid	Spain

Other Sites

Site Name	City	Country
Hospital General Universitario Gregorio Maranon	Madrid	Spain
Hospital Universitario Puerta De Hierro De Majadahonda	Majadahonda	Spain
Hospital Universitari Dexeus Grupo Quironsalud	Barcelona	Spain
Hospital San Pedro De Alcantara	Caceres	Spain
Fundacion Onkologikoa Fundazioa	Donostia / San Sebastian	Spain
Hospital Clinic De Barcelona	Barcelona	Spain
University Clinical Hospital Virgen De La Arrixaca	Murcia	Spain
Hospital General Universitario De Valencia	Valencia	Spain
Area De Salud De Burgos Y Soria	Burgos	Spain
Hvjrffyc Umjzlwgwkoglm Mwimvyv Dh Valdhlaxaq	Santander	Spain
Iohcjjtn Cgclhd Dcsmqbbayxppigjtd	L'hospitalet De Llobregat	Spain
Hpguwlwc Vrhp dnhxrghm	Barcelona	Spain
Hizhpnde Umnwhfxlegdkm de A Cdkywl	A Coruna Galicia	Spain

Trial status

Country	Status	Recruitment Start
Spain	Recruiting	01.03.2025

Trial locations

Investigated drugs:

Encorafenib is a medication used to treat certain types of cancer, specifically melanoma that has a mutation in the BRAF gene. It works by blocking the activity of the BRAF protein, which is involved in the growth and spread of cancer cells. By inhibiting this protein, encorafenib can help slow down or stop the growth of cancer cells.

Binimetinib is another medication used in combination with encorafenib to treat melanoma with a BRAF mutation. It targets a different protein in the cancer cell growth pathway, known as MEK. By blocking MEK, binimetinib helps to further inhibit the growth and spread of cancer cells, enhancing the effect of encorafenib.

Cemiplimab is an immunotherapy drug that helps the body’s immune system fight cancer. It works by blocking a protein called PD-1 on the surface of immune cells. This action allows the immune cells to better recognize and attack cancer cells, helping to control the disease.

Fianlimab is another immunotherapy medication used in combination with cemiplimab. It targets a different protein involved in regulating the immune system’s response to cancer. By working together, fianlimab and cemiplimab can enhance the immune system’s ability to detect and destroy cancer cells, offering a potential treatment option for patients with melanoma.

Investigated diseases:

Malignant melanoma

Melanoma – Melanoma is a type of skin cancer that originates in the melanocytes, the cells responsible for producing melanin, the pigment that gives skin its color. It often begins as a mole that changes in size, shape, or color, but it can also develop on skin that appears normal. As melanoma progresses, it can invade deeper layers of the skin and spread to other parts of the body, including the lymph nodes, liver, lungs, and brain. The disease is known for its ability to metastasize, or spread, rapidly if not detected early. Melanoma can also cause symptoms such as changes in skin texture, itching, or bleeding. Early detection and monitoring of skin changes are crucial in managing the progression of melanoma.

Trial ID:

2024-513375-40-00

Protocol code:

GEM 2301

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Encorafenib, Binimetinib, Cemiplimab, and Fianlimab for Patients with BRAF-Mutated Melanoma and Brain Metastases

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?